



Andrade, C. M. et al. (2020) Increased circulation time of Plasmodium falciparum underlies persistent asymptomatic infection in the dry season. *Nature Medicine*, 26, pp. 1929-1940. (doi: [10.1038/s41591-020-1084-0](https://doi.org/10.1038/s41591-020-1084-0))

The material cannot be used for any other purpose without further permission of the publisher and is for private use only.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

<http://eprints.gla.ac.uk/225803/>

Deposited on 02 November 2020

Enlighten – Research publications by members of the University of  
Glasgow

<http://eprints.gla.ac.uk>

# 1 *Plasmodium falciparum* increased time in circulation underlies persistent asymptomatic 2 infection in the dry season

3  
4 Carolina M. Andrade<sup>1</sup>, Hannah Fleckenstein<sup>1</sup>, Richard Thomson-Luque<sup>1</sup>, Safiatou Doumbo<sup>2</sup>,  
5 Nathalia F Lima<sup>1</sup>, Carrie Anderson<sup>1</sup>, Julia Hibbert<sup>1</sup>, Christine S. Hopp<sup>3</sup>, Tuan M. Tran<sup>4</sup>, Shanping Li<sup>3</sup>,  
6 Moussa Niangaly<sup>2</sup>, Hamidou Cisse<sup>2</sup>, Didier Doumtabe<sup>2</sup>, Jeff Skinner<sup>3</sup>, Dan Sturdevant<sup>5</sup>, Stacy  
7 Ricklefs<sup>5</sup>, Kimmo Virtaneva<sup>5</sup>, Muhammad Asghar<sup>6</sup>, Manijeh Vafa Homann<sup>6</sup>, Louise Turner<sup>7</sup>, Joana  
8 Martins<sup>8</sup>, Erik L. Allman<sup>9</sup>, Marie-Esther N'Dri<sup>10</sup>, Volker Winkler<sup>11</sup>, Manuel Llinás<sup>9</sup>, Catherine  
9 Lavazec<sup>10</sup>, Craig Martens<sup>5</sup>, Anna Farnert<sup>6</sup>, Kassoum Kayentao<sup>2</sup>, Aissata Ongoiba<sup>2</sup>, Thomas  
10 Lavstsen<sup>7</sup>, Nuno S. Osório<sup>8</sup>, Thomas D. Otto<sup>12</sup>, Mario Recker<sup>13</sup>, Boubacar Traore<sup>2</sup>, Peter D.  
11 Crompton<sup>3</sup>, Silvia Portugal<sup>1,14\*</sup>

12  
13 <sup>1</sup> Center of Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg, Germany  
14 <sup>2</sup> Mali International Center of Excellence in Research, University of Sciences, Techniques and Technologies of Bamako, Mali  
15 <sup>3</sup> Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville,  
16 Maryland, USA  
17 <sup>4</sup> Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA  
18 <sup>5</sup> Rocky Mountain Laboratory Research Technologies Section, Genomics Unit, National Institute of Allergy and Infectious Diseases,  
19 National Institutes of Health, Hamilton, Montana, USA  
20 <sup>6</sup> Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm Sweden  
21 and Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden  
22 <sup>7</sup> Centre for Medical Parasitology, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University  
23 of Copenhagen and Department of Infectious Diseases, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark  
24 <sup>8</sup> Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Portugal and ICVS/3B's - PT  
25 Government Associate Laboratory, Portugal.  
26 <sup>9</sup> Department of Biochemistry and Molecular Biology, Huck Center for Malaria Research, The Pennsylvania State University,  
27 Pennsylvania, USA and Department of Chemistry, The Pennsylvania State University, Pennsylvania, USA  
28 <sup>10</sup> Université de Paris, CNRS UMR8104, Inserm U1016, Institut Cochin, Paris, France  
29 <sup>11</sup> Institute of Global Health, Heidelberg University Hospital, Heidelberg, Germany  
30 <sup>12</sup> Institute of Infection, Immunity & Inflammation, MVLS, University of Glasgow, Glasgow, United Kingdom  
31 <sup>13</sup> Centre for Mathematics & the Environment, University of Exeter, Penryn Campus, Penryn, United Kingdom  
32 <sup>14</sup> German Centre for Infection Research (DZIF) \*corresponding author: silvia.portugal@med.uni-heidelberg.de

33  
34 The dry season is a major challenge for *Plasmodium falciparum* parasites in many malaria  
35 endemic regions, where water availability limits mosquitoes to only part of the year. How *P.*  
36 *falciparum* bridges two transmission seasons months apart, without being cleared by the host or  
37 compromising host survival is poorly understood. Here we show that low levels of *P. falciparum*  
38 parasites persist in the blood of asymptomatic Malian individuals during the 5- to 6-month dry  
39 season, rarely causing symptoms and minimally affecting the host immune response. Parasites  
40 isolated during the dry season are transcriptionally distinct from those of subjects with febrile  
41 malaria in the transmission season, reflecting longer circulation within each replicative cycle, of  
42 parasitized erythrocytes without adhering to the vascular endothelium. Low parasite levels  
43 during the dry season are not due to impaired replication, but rather increased splenic clearance  
44 of longer-circulating infected erythrocytes. We propose that *P. falciparum* virulence in areas of  
45 seasonal malaria transmission is regulated so that the parasite decreases its endothelial binding  
46 capacity, allowing increased splenic clearance and enabling several months of subclinical  
47 parasite persistence.

## 48 Introduction

49 The mosquito-borne *Plasmodium falciparum* parasite is responsible for over 200 million malaria  
50 cases yearly, and killed nearly 400,000 African children in 2018<sup>1</sup>. *P. falciparum* causes disease  
51 while multiplying asexually within red blood cells (RBCs) and exporting its variant surface  
52 antigens to the RBC surface. Variant surface antigens mediate adhesion to vascular  
53 endothelium, thereby helping the parasite avoid splenic clearance<sup>2,3</sup>. During each ~48h  
54 replicative cycle in RBCs, *P. falciparum* follows a regulated transcriptional pattern from the  
55 invading merozoite, through the ring- and trophozoite-stages, and to the multinucleated  
56 schizont<sup>4,5</sup>, which yields 16-32 new merozoites. In parallel with a predictable transcriptional  
57 pattern, the parasite develops a network of membrane structures<sup>6</sup> in the infected RBC (iRBC)  
58 and at the trophozoite stage the host cell membrane presents knobs<sup>7</sup> exposing parasite-derived  
59 *P. falciparum* erythrocyte membrane protein 1 (PfEMP1)<sup>8</sup>. The multigene family *var*, is  
60 expressed in a monoallelic fashion, coding for PfEMP1s that bind host endothelial cell  
61 receptors, with different binding phenotypes associating with varying virulence and pathological  
62 outcomes<sup>9</sup>. In Mali and many African regions, malaria cases are restricted to the rainy season  
63 when the mosquitoes transmitting *P. falciparum* are present<sup>10</sup>, while subclinical *P. falciparum*  
64 infections can persist throughout the dry season, enabling the parasite to bridge transmission  
65 seasons several months apart<sup>11-13</sup>. We have recently shown that although *P. falciparum*-specific  
66 humoral immunity is higher in subclinical *P. falciparum* carriers in the dry season, it decreases  
67 similarly during this time in carriers and non-carriers<sup>13</sup>, suggesting that chronic low parasitaemia  
68 in endemic settings may not maintain nor boost malaria immunity. While much is known about  
69 immune responses to clinical malaria, and to some extent to subclinical infections during the  
70 transmission season<sup>14</sup>, the impact on immunity of subclinical *P. falciparum* persistence in the  
71 dry season has not been extensively studied. Host survival during the dry months is essential  
72 for resuming *P. falciparum* transmission in the ensuing rainy season, thus the parasite has likely  
73 evolved strategies to prevent potentially fatal host pathology, and assure persistence during  
74 mosquito-free periods. In this study we address the host and parasite features that associate  
75 with parasite persistence between two transmission seasons, and provide insights into the  
76 complex interaction between *P. falciparum*, its human hosts and the surrounding environment.  
77 By comparing parasites from the dry season to malaria-causing parasites in the transmission  
78 season, we show that despite inducing a minimal immune response and conserving its  
79 replication ability, *P. falciparum* dry season parasitaemias can be maintained low by splenic  
80 clearance of a large proportion of iRBCs that circulate longer than observed in malaria cases.

81

## 82 RESULTS

83 ***P. falciparum* persists during the dry season.** In a cohort study in the Malian village of  
84 Kalifabougou, we followed ~600 individuals from 3 months to 45 years of age during 2017 and  
85 2018. As reported earlier for this site<sup>13</sup>, clinical episodes of malaria (temperature  $\geq 37.5^{\circ}\text{C}$ ,  $\geq 2500$   
86 asexual parasites/ $\mu\text{L}$ , and no other clinically discernible cause of fever) were largely restricted to  
87 the transmission seasons (June - December), whereas nearly all subjects remained free of  
88 symptomatic malaria during the intervening dry seasons (January - May). Specifically, there  
89 were 386 and 347 febrile malaria cases diagnosed during the 2017 and 2018 rainy seasons,  
90 respectively, while only 12 and 5 febrile malaria episodes occurred during the dry seasons  
91 (Fig.1a and Table 1).


92

93 **Table 1** | Characteristics of study participants, clinical cases, and dry season asymptomatic infections stratified by  
94 year

	all			MAL		May	
	n	female %	Age, y, mean (95% CI)	Malaria cases n	Age malaria case (y, 95% CI)	% Pf+ in May n	Age %Pf+ in May (y, 95% CI)
2017	604	46.7	11.2 (10.5 - 11.8)	398	9.4 (8.8 - 10.1)	13.4	13.3 (11.8 - 14.9)
2018	603	46.3	10.8 (10.1 - 11.5)	352	9.2 (8.5 - 10.0)	10.9	11.8 (10.0 - 13.6)

95

96 Despite the very low incidence of clinical malaria in the dry season, we consistently observed  
97 10-20% prevalence of subclinical *P. falciparum* infections during this time. Analysing over 400  
98 individuals with paired data at the beginning (January) and end (May) of each dry season, we  
99 found that 20% of individuals were *P. falciparum* PCR+ in January 2017 and January 2018, and  
100 15% and 12% of individuals were *P. falciparum* PCR+ at the end of the 2017 and 2018 dry  
101 seasons, respectively (Fig. 1b). Older children and young adults carried subclinical *P.*  
102 *falciparum* more frequently than young children at the end of the dry season (Fig. 1c and Table  
103 1), as reported earlier for this cohort<sup>13</sup>. Also, as previously reported, we observed that  
104 subclinical *P. falciparum* carriers at the end of the dry season were very likely to have been  
105 infected since its beginning (January 2017 or January 2018), while uninfected subjects at the  
106 beginning of dry season remained uninfected until its end (Fig. 1b). The odds ratios (OR) of  
107 maintaining the same infection status through the entire dry seasons were OR 90.9 (95% CI  
108 (38.6 , 213.8)  $P < 0.0001$ ) in 2017 and OR Odds ratio 43.5 95% CI (17.5 , 107.5)  $P < 0.0001$ ) in  
109 2018 (Supplementary Table 1). Consistent with the continued absence of clinical malaria during  
110 the dry season, parasitaemias of subclinical carriers determined by RT-qPCR and flow-  
111 cytometry were found to remain low, or in some individuals decline as the dry season  
112 progressed, while clinical cases of malaria in the wet season presented with high parasite  
113 burdens (Fig.1d).




116 **Fig. 1 | *P. falciparum* persists during the 7 dry season.** **a**, Frequency of clinical 8 malaria episodes every 2 days over 2 9 years in a cohort of ~600 subjects aged 3 0 months-45 years. Clinical malaria defined 1 as axillary temperature  $\geq 37.5^{\circ}\text{C}$ ,  $\geq 2500$  2 asexual parasites/ $\mu\text{L}$  of blood, and no 3 other discernible cause of fever. **b**, 4 Prevalence of subclinical *P. falciparum* 5 detected by PCR in paired individuals 6 (rows) at the beginning (Jan), middle (Mar), 7 and end (May) of two consecutive dry 8 seasons (2017 left, 2018 right). Columns 9 are sorted such that the same individual is 0 represented by each row at the three 1 timepoints in each dry season. **c**, Age- 2 stratified point prevalence of subclinical *P.* 3 *falciparum* infection detected by PCR at 4 the end of the dry season in May 2017 (left) 5 and May 2018 (right). **d**, Parasite load 6 detected by qRT-PCR (left) and flow 7 cytometry (right) of RDT+ subclinical 8 children at the beginning (Jan), mid (Mar) 9 and end (May) of the dry season and 0 children with their first clinical malaria 1 episode (MAL) in the wet season. 2 Parasitaemia data represented as median 3  $\pm$  IQR. *P* values determined using Kruskal- 4 Wallis test with multiple comparisons. 5

. 6

147 ***P. falciparum* induces a minimal immune response during the dry season.** To test the 148 hypothesis that host immunity may contribute to the suppression of parasitaemia during the dry 149 season, we compared the immune responses of subclinical carriers of *P. falciparum* (May+) 150 versus non-infected children (May-). We profiled serological markers of inflammation and 151 cytokines, circulating immune cells, and humoral responses to *P. falciparum* variant surface 152 antigens (VSAs) of age- and gender-matched children who did or did not carry *P. falciparum* 153 during the dry season, as detected retrospectively by PCR. Inflammation markers that had been 154 reported to be elevated in clinical cases of malaria, such as C-reactive protein (CRP)<sup>15</sup>, von 155 Willebrand factor (vWF)<sup>16</sup>, and hepcidin<sup>17</sup> were quantified in plasma samples obtained at the 156 beginning (Jan) and end (May) of the dry season. None of the three markers were significantly 157 different in subclinical carriers compared to uninfected children at either timepoint (Fig. 2a). We 158 complemented these serological analyses with a multiplex bead array to detect 32 cytokines

159 and chemokines and observed no differences between children with or without *P. falciparum* at  
160 the end of the dry season (May) in all but one of the quantified analytes (Supplementary Table  
161 2). Only CXCL1, a pro-inflammatory chemokine known to recruit neutrophils, that has thus far  
162 not been associated with malaria in the clinical setting, was significantly increased in children  
163 with *P. falciparum* persistent parasitaemias at the end of the dry season (Fig. 2b). In contrast,  
164 CCL3, IL-10, IL-6 and IL-1 $\beta$ , previously associated with clinical malaria<sup>18-20</sup> were comparable in  
165 the plasma of infected versus uninfected children at the end of the dry season (Fig. 2b and  
166 Supplementary Table 2). We next quantified the proportions of major leucocyte populations from  
167 thawed PBMCs collected at the end of the dry season from children with or without subclinical  
168 *P. falciparum* (gating strategy in Supplementary Fig. 1). We observed that monocytes, T cells, B  
169 cells and NK cell subpopulations were not significantly different between children who carried  
170 (May+), or not (May-) *P. falciparum* (Fig. 2c and Supplementary Fig. 2). To interrogate  
171 differences in cell function, we quantified intracellular cytokines, activation or cytotoxicity  
172 markers, transcription factors or exhaustion markers of freshly collected PBMCs from *P.*  
173 *falciparum* subclinical infected- and non-infected children at the end of the dry season. The  
174 levels of the activation marker CD25, transcription factor T-bet or cytokine IL-2 of CD4 T cells;  
175 Granzyme B of CD8 T and NK cells, and exhaustion marker FCRL5 of atypical memory B cells  
176 were comparable between children who carried or not *P. falciparum* (Fig. 2d and Supplementary  
177 Table 3). We further questioned whether memory B cells (MBCs defined as CD19+, CD10-,  
178 CD21- and CD27+ or -, gating strategy in Supplementary Fig. 1) specific for *P. falciparum* were  
179 affected in subclinical carriers compared to non-infected individuals at the end of the dry  
180 season. Using biotinylated AMA-1 and MSP1<sub>21</sub>, we quantified AMA-1- or MSP1-specific MBCs  
181 in both children who carried *P. falciparum* parasites, and non-infected children at the end of the  
182 dry season. We found that the proportion of class-switched *P. falciparum*-specific MBCs (AMA1+  
183 or MSP1+ IgG+ IGM- MBCs) was significantly increased in subclinical carriers at the end of the  
184 dry season, while no such difference was found in non-class-switched MBC population (AMA1+  
185 or MSP1+ IgG- IGM+ MBCs) (Fig. 2e). Within the IgG+ MBC subpopulations (classical, activated  
186 or atypical) we failed to observe differences between *P. falciparum* carriers and uninfected  
187 individuals at the end of the dry season in *P. falciparum*-specific classical and atypical MBCs,  
188 but detected increased *P. falciparum*-specific activated MBCs in subclinical carriers  
189 (Supplementary Fig. 2). Using another multiplex bead array, we quantified humoral responses  
190 of *P. falciparum* subclinical carriers and uninfected individuals at the beginning and end of the  
191 dry season, to 35 different domain types of the VSA multigene family *var*, which were grouped  
192 according to their endothelial-receptor affinity (CD36, EPCR or unknown receptor) and PfEMP1


193 UPS type (A, B or B/A types)<sup>22</sup> (Supplementary Table 4). We observed that more subclinical  
194 carriers (May<sub>+</sub>) than non-infected individuals (May<sub>-</sub>) were reactive against PfEMP1 domains  
195 binding to CD36, EPCR or to unknown receptors at both time-points, and also that the  
196 proportion of individuals reactive to the different PfEMP1 domains decreased over the dry  
197 season independently of individual infectious status (Fig. 2f and Supplementary Fig. 2), these  
198 differences parallel our previously published data on *P. falciparum*-specific humoral responses  
199 to non-VSA<sub>13</sub>, suggesting comparable humoral dynamics for PfEMP1s and non-VSA antigens.  
200 Additionally, we observed that the magnitude of IgG reactivity to A, B or B/A types of PfEMP1  
201 declined similarly from the beginning to end of the dry season in children who carried subclinical  
202 infection (May<sub>+</sub>) or were uninfected (May<sub>-</sub>) during the dry season (Fig. 2g and Supplementary  
203 Fig. 2). Antibodies against PfEMP1 domains (Fig. 2f-g), against a large set of *P. falciparum* non-  
204 VSA<sub>13</sub>, and also particularly against RBC invasion-related proteins<sup>23</sup> (Supplementary Fig. 2)  
205 were consistently higher in subclinical carriers compared to non-infected children at the end of  
206 the dry season, so we questioned if the difference in humoral response at the end of the dry  
207 season could impose variance in inhibition of merozoite invasion in vitro. We tested merozoite  
208 invasion of a laboratory-adapted *P. falciparum* strain in the presence of plasma from Malian  
209 children who carried parasites or not during the dry season, and evaluated the antibodies' ability  
210 to block RBC invasion. Testing complete and antibody-depleted plasma, we observed that  
211 antibody-depleted Malian plasma allowed for ~5-fold increase in invasion of merozoites  
212 compared to complete Malian plasma, while antibody depletion had no differential effect on the  
213 control German plasma used (Fig. 2h and Supplementary Fig. 2). Notably, however, plasma  
214 from Malian children carrying subclinical infections (May<sub>+</sub>) or not carrying parasites (May<sub>-</sub>), had  
215 similar ability to inhibit merozoite invasion, suggesting that the antibodies remaining elevated at  
216 the end of the dry season have no significant effect on inhibiting merozoites invasion of RBCs,  
217 and are unlikely to contribute to the maintenance of low parasitaemias through this mechanism.  
218



**1 Fig. 2 | *P. falciparum* induces a**  
**2 minimal immune response during**  
**3 the dry season. a,** Plasma  
**4 concentration of C-reactive protein**  
**5 (CRP) (May- n=71; May+ n=117),**  
**6 von Willebrand factor (vWF) (May-**  
**7 n=33; May+ n=51) and Hepcidin**  
**8 (May- n=41; May+ n=37) of paired**  
**9 samples at the beginning (Jan) and**  
**0 end of the dry season (May) carrying**  
**1 *P. falciparum* (May+) or not (May-).**  
**2 Boxplots indicate median, 25<sup>th</sup> and**  
**3 75<sup>th</sup> percentiles, *P* values determined**  
**4 using one-way ANOVA with multiple**  
**5 comparisons correction. b,** Plasma  
**6 concentration of cytokines from**  
**7 children carrying (May+ n=21) or not**  
**8 (May- n=12) *P. falciparum* infection**  
**9 at the end of the dry season. ANOVA**  
**0 with Sidak multiple comparisons test.**  
**1 c,** Expression of surface markers of  
**2 frozen PBMCs collected from**  
**3 children that carried (May+) or not**  
**4 (May-) *P. falciparum* at the end of the**  
**5 dry season. Data represented as**  
**6 median ± IQR. *P* values determined**  
**7 using Kruskal-Wallis test with**  
**8 multiple comparisons. d,** Expression  
**9 of intracellular markers of freshly**  
**0 collected PBMCs from children that**  
**1 carried (May+) or not (May-) *P.***  
**252 *falciparum* at the end of the dry**

**253 season. Data represented as median ± IQR. *P* values determined using Kruskal-Wallis test with**  
**254 multiple comparisons. (Supplementary Table 3 for details). e,** *P. falciparum*-specific memory B  
**255 cells (MBCs), defined as AMA1+ or MSP1+, in *P. falciparum* carriers (May+ n=23) or non-carriers**  
**256 (May- n=28) at the end of the dry season for class-switched (IgG+ IGM- MBCs) or non-class**  
**257 switched (IgG- IGM+ MBCs). Data represented as median ± IQR. *P* values determined by Mann-**  
**258 Whitney test. f,** Proportion of children with antibodies specific to PfEMP1 domains with different  
**259 binding activity at the beginning (Jan) and end (May) of the dry season (Jan and May- n=106; Jan**  
**260 and May+ n=112). Boxplots indicate median, 25<sup>th</sup> and 75<sup>th</sup> percentiles, *P* values determined with**  
**261 RM one-way ANOVA (with Greenhouse-Geisser correction) for each of the binding receptor affinity. g,**  
**262 Magnitude of anti-PfEMP1 domains of A and B subtypes between the beginning and end of the**  
**263 dry season in children carrying or not subclinical *P. falciparum* (Jan and May+ n=112, Jan and**  
**264 May- n=106). h,** Parasitaemia after invasion in the presence of complete plasma or antibody-  
**265 depleted plasma from children who carried (May+ n= 29) or not (May- n= 24) *P. falciparum***  
**266 subclinical infections during the dry season. Data represented as median ± IQR. *P* values**  
**267 determined using Kruskal-Wallis test with multiple comparisons.**

269 ***P. falciparum* genetic diversity is maintained throughout the year.** Next, we asked whether  
 270 *P. falciparum* parasites that persist through the dry season are genetically distinct from those  
 271 that cause acute malaria during the transmission season. To that end, we measured the size of  
 272 the merozoite surface protein 2 gene (*msp2*), which is highly polymorphic and discriminates  
 273 different *P. falciparum* genotypes<sup>24,25</sup>. Through nested PCR followed by fragment analysis using  
 274 capillary electrophoresis, we compared paired samples from 93 subclinical carriers at the  
 275 beginning (Jan) and end (May) of the dry season, with 136 samples from clinical cases of  
 276 malaria in the ensuing transmission season (MAL). The number of clones detected per  
 277 individual did not significantly differ between parasites isolated during the dry season or  
 278 transmission season, nor did the percentage of individuals with different numbers of clones  
 279 (Fig.3a-b). Furthermore, the size and distribution of *msp2* clones identified during the dry  
 280 season were similar to those isolated from clinical malaria cases during the transmission season  
 281 (Fig.3c-d), with the most frequent clone sizes being the same at any of the time-points analysed.  
 282  
 283 **Figure3**




284 **Fig. 3 | *P. falciparum* genetic diversity is maintained throughout the year.** **a**, Number  
 5 of *P. falciparum* clones in subclinical PCR+  
 6 children in beginning (Jan) and end (May) of the  
 7 dry season, and first clinical malaria case (MAL)  
 8 during the transmission season, determined by  
 9 size differences in the polymorphic region of  
 10 *msp2*. **b**, Proportion of individuals with different  
 11 number of *P. falciparum* clones in the beginning  
 12 (Jan) and end (May) of the dry season and  
 13 clinical malaria cases (MAL). **c**, Size of the  
 14 *msp2* alleles FC27 (left) and IC/3D7 (right) in  
 15 beginning (Jan) and end (May) of the dry  
 16 season, and clinical malaria cases (MAL). **d**,  
 17 Prevalence of different *msp2* clone sizes of  
 18 FC27 (left) and IC/3D7 (right) allelic families in  
 19 Jan (n= 93), May (n= 93) and clinical malaria  
 20 (MAL, n= 136). Comparisons were performed  
 21 with Mood's median test.

303

304 **Transcriptome of circulating subclinical *P. falciparum* at the end of the dry season differs**  
 305 **from that of *P. falciparum* during clinical malaria.** We performed RNA sequencing of  
 306 leucocyte-depleted blood from 12 children with persistent subclinical *P. falciparum* at the end of  
 307 the dry season (May), and from 12 age- and gender- matched children presenting with their first  
 308 clinical malaria case in the ensuing transmission season (MAL). RNA-Seq libraries from these  
 309 samples were run on an Illumina HiSeq, producing 0,5 to 3 million reads mapping uniquely to

310 the *P. falciparum* genome (Supplementary Table 5). Principal component (Fig. 4a) and  
311 unsupervised clustering (Fig. 4b) analyses showed segregation of transcription profiles based  
312 on seasonality. Differentially expressed genes (DEGs) determined at a false discovery rate  
313 threshold of 5% resulted in 1607 DEGs, 1131 transcripts up-regulated, and 476 transcripts  
314 down-regulated in the dry season compared to clinical malaria samples (Fig. 4c and  
315 Supplementary Table 6). Validation of the RNA-Seq data was performed by RT-qPCR of eight  
316 DEGs and the correlation between the two methods resulted in highly significant  $r_2=0.929$  (Fig.  
317 4d and Supplementary Table 7). Furthermore, samples from additional children (6 end of the dry  
318 season and 12 malaria cases during the transmission season) were used to quantify expression  
319 of three DEGs in parallel with the initial 24 samples, and revealed similar fold changes by RT-  
320 qPCR (Fig. 4e). We investigated similarities in the DEGs obtained in this study with those of  
321 previous reports comparing parasite physiological states and transcriptomes from a range of  
322 clinical malaria severities<sup>26</sup>, or parasites causing malaria in high versus low transmission  
323 areas<sup>27</sup>, but no enrichment was found (Supplementary Fig. 3), suggesting that singular  
324 mechanisms may be at play during the dry season. Functional and Gene Ontology analysis of  
325 the dry season DEGs using *DAVID* revealed a significant enrichment (Benjamini-Hochberg  
326 adjusted  $P < 0.05$ ) of transcripts involved in cellular processes related with several metabolic  
327 pathways and also *Phagosome*, *DNA replication* or *Homologous recombination* (Fig. 4f).  
328 Indeed, DEGs involved in metabolic pathways suggest that *Glycolysis*, *Glycerophospholipid*,  
329 *Purine and Pyrimidine* pathways were increased in parasites from the end of the dry season  
330 (May), while *Fatty acid biosynthesis*, appeared downregulated comparing to parasites from  
331 clinical malaria (MAL) in the wet season (Fig. 4g). To follow-up on possible metabolic  
332 differences between parasites persisting through the dry season and parasites causing malaria  
333 in the transmission season we used liquid chromatography–mass spectrometry to profile both  
334 hydrophilic and hydrophobic metabolites from the plasma of 12 subclinical children with *P.*  
335 *falciparum* infections at the end of the dry season (May), and of 12 children presenting with their  
336 first clinical malaria case (MAL) in the rainy season. We found significant separation between  
337 metabolites present in the two groups of samples (Fig. 4h and Supplementary Table 8),  
338 however the difficulty of normalization of measured metabolite levels to parasite burden, plus  
339 the strong parasitaemia differences at the time of the blood draw, hinder conclusive  
340 interpretation of what may be seasonal or parasite induced metabolic alterations  
341 (Supplementary Table 9).  
342

343 **Figure 4**



**4 Fig. 4 | Transcriptome of 5 circulating *P. falciparum* 6 at the end of the dry 7 season differs from 8 malaria-causing *P. 9 falciparum* during the 0 transmission season. a, 1 Principal components 2 analysis and b, 3 Unsupervised clustering 4 analyses of RNA-Seq data 5 of *P. falciparum* parasites 6 collected at the end of the 7 dry season (May, n= 12) 8 and from clinical malaria 9 cases (MAL, n= 12). c, 0 Heatmap showing 1 normalized reads of 2 differentially expressed 3 genes (DEGs) (rows) for 4 each subject (columns) 5 from *P. falciparum* collected 6 at the end of the dry season 7 (May, n=12) and at the first 8 clinical malaria case (MAL, 9 n=12) in the ensuing 0 transmission season. 1 Analysis performed using 2 Bioconductor package 3 DESeq2, with  $P_{adj} < 0.05$  4 considered significant. d, 5 RT-qPCR validation of 6 RNA-Seq data for 8 labelled 7 DEGs (n= 24).  $P$  and  $r_2$  8 values were determined 9 using Pearson correlation.**


381 initial 24 samples used in RNA-Seq analysis (left) and 18 additional samples (right) for three  
 382 DEGs. Data represented as mean  $\pm$  SD  $P$  values determined with non-parametric Mann-Whitney  
 383 test. f, Summary of KEGG pathways significantly enriched with DEGs in dry season obtained  
 384 using the DAVID tool. Blue bars indicate  $P_{adj}$  for the enrichment of each pathway in the gene list.  
 385 The grey dashed line indicates the threshold  $P = 0.05$ . The orange line indicates the percentage  
 386 of genes in each pathway that was present in the DEG list. g, Heatmap showing normalized reads  
 387 of differentially expressed genes (DEGs) involved in different metabolic pathways (rows) for each  
 388 subject (columns) from *P. falciparum* collected at the end of the dry season (May, n=12) and at  
 389 the first clinical malaria case (MAL, n=12) in the ensuing transmission season. h, Principal  
 390 components analysis of target metabolites' data of plasma samples from subclinical *P. falciparum*  
 391 carriers at the end of the dry season (May, n=12) and from clinical malaria cases (MAL, n=12).  
 392

393 ***P. falciparum* replication is not impaired in the dry season.** We then tested the hypothesis  
394 that dry season parasitaemias were maintained low and subclinical due to decreased parasite  
395 replication capacity during this period. We cultured *P. falciparum* in vitro directly after blood  
396 draw for 36 to 48 h, from rapid diagnostic test positive (RDT+) samples of asymptomatic  
397 individuals at three time points of the dry season (January, March and May), and from samples  
398 of children presenting with their first clinical malaria episode of the ensuing transmission season  
399 (MAL). By flow cytometry, we measured the increase in parasitaemia and parasite development  
400 at 0, 16, 24, 30, 36 and 48 h after in vitro culture. Parasite in vitro growth rates of samples from  
401 >40 subclinical donors during the dry season, and ~30 malaria cases in the transmission  
402 season indicated that the highest growth determined between any two time-points of the short-  
403 term culture was similar throughout the year. Parasitaemias increase in vitro between 2 and 5-  
404 fold at any point in the year, 2.8-fold in January, 95% CI (2.3 , 3.3), 4.1-fold in March, 95% CI  
405 (3.4 , 4.7), 3.6-fold in May, 95% CI (2.6 , 4.6), and 2.8-fold in malaria cases, 95% CI (2.1 , 3.5).  
406 However, the number of hours in culture needed to increase parasitaemia was shorter in the dry  
407 season samples than in samples from malaria-causing parasites in the transmission season  
408 (Fig. 5a). In accordance with an earlier increase in parasitaemia in vitro during the dry season,  
409 we could frequently identify on Giemsa smears mature schizonts after 16 and 24 h of culture,  
410 and young ring-stages after 30 or 36 h in the dry season samples; while mature schizonts of  
411 malaria-causing parasite samples were mostly observed after 36 h in culture and young ring-  
412 stages were largely found after 48 h in vitro (Fig. 5b). When we calculated the number of hours  
413 in culture at which the highest increase of parasitaemia could be detected for each sample, we  
414 observed that it decreased from the beginning to the end of the dry season, Jan 26.4 h, 95% CI  
415 (24.5 , 28.3), Mar 24.9 h, 95% CI (23.9 , 25.9), May 22.7 h, 95% CI (20.8 , 24.6), and was  
416 maximum during malaria cases in the transmission season, MAL 44.0 h , 95% CI (41.5 , 46.6)  
417 (Fig. 5c). Nevertheless, when we measured the number of merozoites per multinucleated  
418 schizont prior to or at the time of the highest increase in parasitaemia in vitro, we obtained  
419 comparable values at the end of dry season and in clinical malaria cases in the wet season (Fig.  
420 5d). Finding later developmental parasite stages at earlier times in this short-term in vitro  
421 experiment during the dry season could indicate a faster than 48 h intraerythrocytic replicative  
422 cycle, or alternatively, that dry season parasites circulate longer without adhering to the host  
423 vascular endothelium, and are more developed than circulating parasites in clinical malaria  
424 cases at the time of the blood draw. To test the latter, we used the RNA-seq data described in  
425 Fig. 4 to estimate, with a likelihood-based statistical method previously described<sup>28</sup>, the age in  
426 hours post-invasion (hpi) of circulating parasites from subclinical children at the end of the dry

427 season (May) and from clinical cases during the wet season (MAL). We determined that  
 428 parasites circulating in the dry season had a transcriptional signature of ~17 hpi, 95%CI (14.05 ,  
 429 20.8), while parasites circulating in malaria cases during the wet season had a transcription  
 430 profile comparable to parasites with ~7 hpi, 95% CI (6.5 , 7.7) (Fig. 5e). Accordingly, by imaging  
 431 the thick blood films made in the field at the time of the blood draw, we confirmed that  
 432 trophozoites were present on the end dry season samples, while clinical malaria samples in the  
 433 transmission season had only ring-stages, with much smaller areas (Fig. 5f-g).

434

435 **Figure 5**



6 **Fig. 5. | Replication of 7 persistent dry season *P. falciparum* is not impaired.**

8 **a**, Parasitaemia fold change at  
 9 0 16, 24, 30 and 36 h post-  
 1 culture of parasites collected  
 2 from children at different times  
 3 during the dry season (Jan,  
 4 Mar and May) and clinical  
 5 malaria case (MAL). Fold  
 6 change is defined as %iRBC  
 7  $t(n) / \%iRBC t(n-1)$ . Data is  
 8 represented as median  $\pm$  IQR.  
 9 Dashed line drawn at fold  
 0 change of 1. **b**, Giemsa-  
 1 stained thin blood smears 16,  
 2 24, 36 or 48 h post-culture of  
 3 *P. falciparum* parasites  
 4 collected from children during  
 5 the dry season (Jan, Mar and  
 6 May) and clinical malaria case  
 7 (MAL). Scale bars, 2  $\mu$ m **c**,  
 8 Time of highest increase in  
 9 parasitaemia detected during

460 in vitro culture of *P. falciparum* parasites collected from children in Jan, Mar and May during the  
 461 dry and clinical malaria case (MAL). Data represented as mean  $\pm$  SD *P* values determined using  
 462 Kruskal-Wallis multiple comparisons test. **d**, Number of merozoites inside multinucleated  
 463 schizonts determined by flow cytometry at the end of the dry season (May) and clinical malaria  
 464 (MAL) samples. **e**, Maximum likelihood estimation (MLE) of the hours post-invasion of dry season  
 465 (May) and clinical malaria (MAL) parasites. Data is represented as mean  $\pm$  SD *P* values  
 466 determined using Mann-Whitney test. **f**, Giemsa-stained thick blood films of *P. falciparum*  
 467 parasites collected straight from the arm of children, at the end of the dry season (May) and at  
 468 their first clinical malaria (MAL). Scale bars, 5  $\mu$ m. **g**, *P. falciparum* area measured from Giemsa-  
 469 stained thick smears in subclinical infections at the end of the dry season (May) and in malaria  
 470 cases (MAL) in the wet season. Data is represented as median  $\pm$  IQR.

471

472 **Infected erythrocytes in circulation at the end of the dry season are at higher risk of**  
473 **splenic clearance.** To investigate if longer circulation of iRBCs in the dry season would impact  
474 host RBC deformability and potentiate splenic clearance, we used a microsphiltration system  
475 that mimics the narrow and short inter-endothelial slits of the human spleen with different sized  
476 microspheres<sup>29</sup>. Using freshly collected blood samples from asymptotically infected children  
477 at the end of the dry season and from children presenting with febrile malaria during the  
478 transmission season, we assessed retention in the microspheres and flow-through of circulating  
479 iRBCs at time zero, and after 6, 18 and 30 h in vitro. We observed that iRBCs collected from  
480 malaria (MAL) cases were not significantly retained in the spleen-like system at 0, 6 or 18 h  
481 post-culture, and that only after 30 h was the percentage of iRBCs in the flow-through reduced,  
482 indicating splenic retention of iRBCs (Fig. 6a). Conversely, iRBCs in RDT+ blood collected at the  
483 end of the dry season (May) had significantly reduced flow-through immediately after the blood  
484 draw (~25% retention of 0 h iRBCs in the microsphere-system), and over 50% retention of  
485 iRBCs after 6 h or 18 h in culture (Fig. 6a). Accordingly, we observed that trophozoites or  
486 schizonts which fail to flow through the microsphere system were circulating (at 0 h) only in the  
487 dry season samples (Fig. 6b).

488 We then investigated whether differences in cytoadhesion, affecting the length of time that  
489 parasitized cells remain in circulation, could explain the observed age distributions and  
490 microsphiltration results. For this we used a mathematical model to describe the within-host  
491 growth and removal of infected red blood cells (iRBC) from circulation through cytoadhesion in  
492 the deep vasculature and through splenic retention (see Methods). Both processes were  
493 assumed to be dependent on the parasite's developmental stage, increasing as the parasite  
494 starts to express adherence-mediating surface antigens and RBC modification leads to higher  
495 cell rigidity. Whereas cytoadhering parasites still replicate, those filtered out by the spleen were  
496 assumed to be completely removed. As shown in Fig. 6c, effective growth rates and population  
497 sizes of low-cytoadhering parasites are significantly lower than those of high-cytoadhering  
498 parasites, which can avoid splenic clearance before parasitized cells become too rigid to pass  
499 through the spleen. We then obtained estimated parasite age distributions for both scenarios  
500 (Fig.6d) by sampling from the modelled parasite population at random points over the simulated  
501 infection time course, akin to blood sampling from a population. As low-adhesion parasites are  
502 predominantly removed by the spleen towards the end of their life-cycle, they show a much  
503 broader age-range than high-cytoadhesion parasites, which are removed from circulation earlier  
504 through cytoadhesion and therefore show a narrower and younger age range, in agreement with  
505 the observed age distribution from thick blood smears (Fig. 5e-f). Next, we simulated a

506 microfiltration experiment by “growing” our sampled model parasites older and evaluating  
507 their projected average flow-through based on our assumed, age-dependent splenic retention  
508 function (see Methods). As illustrated in Fig. 6e, the throughput of high-cytoadhering parasites is  
509 high for the first 6-10h before dropping off gradually as parasites grow older. In contrast,  
510 samples from low-cytoadhering parasites with their more uniformly distributed age range  
511 already have a much-reduced flow-through at 0 h, which, however, remained more stable as  
512 parasites mature over the next 30h; this is again in line with empirical observations (Fig. 6a).  
513 These mathematical results suggest that cytoadhesion alone can explain the differences  
514 between parasites sampled during the dry season (low-adhesion) and parasites sampled from  
515 malaria cases (high-adhesion).  
516 To investigate if the expression of cytoadhesion-mediating PfEMP1 proteins differed in  
517 abundance or quality in parasites found subclinical in the dry season and parasites found in  
518 malaria cases during the wet season, we assembled the *var* genes from the RNA-Seq reads of  
519 the 24 samples from end of the dry season and malaria cases (see methods). Expression of  
520 several *var* genes has been shown to remain fairly stable between ~10 and 20h post invasion<sup>30</sup>  
521 which should be close to the average ages estimated for parasites in malaria cases’ and dry  
522 season samples respectively. Using a recently developed analytical pipeline<sup>31</sup>, we could detect  
523 LARSFADIG motifs identifying PfEMP1 coding genes<sup>32</sup> in 8 out of 12 samples from the dry  
524 season, and in 10 out of 12 malaria cases (Table 2).

525  
526

527 **Table 2** | LARSFADIG motifs that identify PfEMP1 coding genes of 12 subclinical individuals at the end of the dry  
528 season (May) and 12 first clinical malaria episodes in the ensuing wet season (MAL).

SampleID	de novo assembly					Mapped base approach		
	total length in bp	# contigs	#LARSFADIG	Max expression	longest contig in bp	# varDB hits	Id of var gene with highest hit	Domain structure of highest hit
May 9307	18.920	10	1	50	6.763	2.693	PF0159-C.g637	NTS-DBLa-CIDRa-DBLb-DBLg-DBLd-CIDRb-DBLb-DBLg-
May 9308	9.624	5	1	37	5.348	14	PF0145-C.g513	NTS-DBLa-CIDRa-DBLd-CIDRb-
May 9309	1.296	2	0	NA	670	13	PF0084-C.g173	NTS-DBLa-CIDRa-DBLd-CIDRb-
May 9310	18.769	10	3	87	6.227	216	PF0043-C.g402	DBLd-CIDRb-
May 9311	2.292	1	0	NA	2.292	14	PT0294-C.g1327	DBLa-CIDRa-DBLb-DBLg-DBLd-CIDRb-DBLb-DBLg-
May 9312	20.556	18	1	30	3.170	64	PF0051-C.g887	DBLa-CIDRa-DBLd-CIDRb-
May 9313	4.721	8	0	NA	2.292	6	PT0122-C.g1412	NTS-DBLa-CIDRa-DBLb-DBLz-DBLe-
May 9314	39.049	28	2	66	9.011	248	PF0262-C.g611	DBLb-DBLb-DBLd-CIDRg-
May 9315	5.824	3	1	307	4.176	193	PF0062-C.g430	NTS-DBLa-CIDRa-DBLd-CIDRb-
May 9316	9.185	13	0	NA	3.400	121	PA0182-C.g826	NTS-DBLa-CIDRa-
May 9317	19.689	20	2	176	5.234	915	PM0098-C.g1086	NTS-DBLa-CIDRa-DBLd-CIDRg-
May 9318	10.131	10	1	55	6.004	51	PF0417-C.g422	NTS-DBLa-CIDRa-DBLd-CIDRb-
MAL 9319	173.674	133	24	159	10.423	1.299	PA0146-C.g1029	DBLd-CIDRb-
MAL 9320	8.666	20	0	NA	2.208	66	PA0224-C.g312	DBLa-CIDRa-DBLd-CIDRb-
MAL 9321	23.668	12	2	1,263	9.564	1.149	PF0097-C.g294	NTS-DBLa-CIDRa-DBLb-DBLg-DBLd-CIDRb-
MAL 9322	138.491	170	16	104	10.046	846	PA0092-C.g461	DBLd-CIDRg-DBLg-DBLz-
MAL 9323	35.909	43	5	48	3.571	103	PA0253-C.g804	NTS-DBLa-CIDRa-DBLd-CIDRb-
MAL 9324	43.517	56	5	27	4.626	136	PF0189-C.g397	DBLd-CIDRb-
MAL 9325	3.849	1	0	NA	3.849	391	PF0801-C.g1202	DBLg-DBLz-DBLe-DBLe-
MAL 9326	113.437	87	17	71	8.812	785	QG0212-C.g1592	NTS-DBLa-CIDRa-DBLd-CIDRb-
MAL 9327	11.330	14	2	109	4.225	82	PA0237-C.g706	NTS-DBLa-CIDRa-DBLd-CIDRb-
MAL 9328	12.501	16	1	163	2.688	63	PF0228-C.g1045	CIDRa-DBLd-CIDRb-
MAL 9329	122.076	120	17	1.140	9.161	1.288	PA0167-C.g886	NTS-DBLa-CIDRa-DBLd-CIDRg-
MAL 9330	106.347	87	13	85	11.752	420	PT0211-C.g738	NTS-DBLa-CIDRa-DBLb-DBLd-CIDRb-


529

530

531 We were able to annotate some full length *var* genes, including both the start N-terminal  
532 sequence (NTS) and the acidic terminal sequence (ATS) domains, and also many isolated  
533 fragments, and generally we observed more contigs with LARSFADIG motifs and *var* gene  
534 fragments in the wet season samples (Supplementary Table 10). We used different methods to  
535 access an enrichment of higher expressed *var* genes in the wet versus the dry season samples.  
536 Although we did not see statistically significant enrichment, we observe a trend that the top  
537 expressed *var* genes in each individual in the wet season are higher expressed (Fig. 6f).  
538 Furthermore, we identified known *var* gene domains such as Duffy Binding Like (DBL) and  
539 Cysteine Rich Interdomain Regions (CIDR) as well as the NTS and ATS, and searched for  
540 typical 5' upstream (UPS) sequences associating with different pathological outcomes<sup>22</sup> in the  
541 dry season and malaria cases' assembled *vars*. Although we were unable to determine the UPS  
542 type of expressed *vars* due to the short assembly of the 5' UTR region, we did find more *var*  
543 genes with a DBLz domains in the malaria samples (13 out of 61 in *var* fragments longer than  
544 3.5 kb) compared to the dry season (1 out of 11 in *var* fragments longer than 3.5 kb)  
545 (Supplementary Table 10).

546

547 **Figure 6**



**Fig. 6 | Infected erythrocytes in circulation at the end of the dry season are at higher risk of splenic clearance. a, *P. falciparum* iRBCs filtration through beads mimicking the human spleen at 0, 18 and 30 h post culture at the end of the dry season (May) and during clinical malaria (MAL) relative to the non-filtered same-time control. Flow-through % is defined as downstream %iRBCs / upstream %iRBCs  $\times 100$  ( $n = 8$ , mean  $\pm$  SD,  $P$  values determined by Dunn's multiple comparison test of the mean rank of each condition to 10h MAL, \* shows  $P < 0.001$ ) b, Percentage of circulating non-ring stage iRBCs at the end of the dry season (May,  $n = 50$ ) and during malaria cases (MAL,  $n = 39$ ) determined by flow cytometry. Mean  $\pm$  SD  $P$  values determined with Mann-Whitney test. c, Within-host dynamics simulation of growth rates and population sizes over five replication cycles of low-cytoadhering (left), and high-cytoadhering (right) parasites, stratified as circulating (red lines), cytoadhering (orange dashed lines) and total biomass (black lines). d, Simulation of**

574 circulating parasites' age distribution over two replication cycles after repeated sampling of low-  
 575 cytoadhering parasites (Low), and high-cytoadhering parasites (High). e, Simulation of circulation  
 576 and passage through the spleen of parasites aging over time, with low-cytoadhering (Low), and  
 577 high-cytoadhering (High) parasites. f, Expression level of the highest expressed var gene at the  
 578 end of the dry season (May,  $n = 8$ ) and during a clinical malaria case (MAL,  $n = 10$ ).  
 579

**580 Discussion**

581 Asymptomatic individuals carrying *P. falciparum* at the end of the dry season in areas of  
 582 seasonal malaria have been broadly described<sup>13,33-37</sup>, but how the parasite bridges two rainy  
 583 seasons without promoting malaria symptoms or being cleared remained elusive. In this study,  
 584 with samples from Malians exposed to alternating six-month dry and transmission seasons, we  
 585 show that within each 48h replicative cycle, *P. falciparum* iRBCs circulate longer in the  
 586 bloodstream during the dry season, allowing increased clearance in the spleen, and thus  
 587 preventing high parasitaemias which could lead to immune activation or malaria symptoms<sup>38,39</sup>.  
 588 Although asymptomatic parasitaemia at the end of the dry season is associated with a lower risk  
 589 of clinical malaria in the ensuing wet season<sup>13,33-35</sup>, clearance of parasitaemia with anti-malarials  
 590 prior to the transmission season does not increase subsequent malaria risk, and the persistence

591 of infection during the dry season does not prevent nor slow the decline of *P. falciparum*-specific  
592 antibodies<sup>13</sup> (Fig. 2 f-g). Consistent with these earlier observations, low parasitaemia during the  
593 dry season did not elicit detectable inflammation, nor affect immune cell function (Fig. 2),  
594 possibly indicating that chronic low parasitaemia in seasonal endemic settings might differ from  
595 Controlled Human Malaria Infections in naïve individuals, where low-level parasitaemias appear  
596 to induce immunity (reviewed in<sup>40</sup>); and also pointing that slow and continuous stimulation of the  
597 immune system is less effective than sudden changes in antigenic stimulation<sup>41</sup>. Nevertheless,  
598 cumulative immunity may be determinant to sustain the dry season reservoir of *P. falciparum*.  
599 Dry season subclinical carriers have higher anti-*P. falciparum* humoral immunity (Ref. 13 and  
600 Fig. 2f-g), and higher *P. falciparum*-specific MBCs (Fig. 2e) than non-infected individuals,  
601 suggesting that a certain cumulative exposure is necessary to carry subclinical infections  
602 through the dry season. Additionally, we and others have shown that end of dry season  
603 parasitaemias are more frequent in older than younger children<sup>13,42</sup>, which is consistent with an  
604 age-dependent decrease in parasitaemia and increase in anti-parasitic immunity<sup>43,44</sup>. It is  
605 possible that within each *P. falciparum* infection, sequential presentation on the surface of  
606 iRBCs of the different variants of multi-gene families, and its corresponding ordered acquisition  
607 of antibodies<sup>45,46</sup> favours progressively less virulent parasites. Accordingly, a recent study of  
608 Controlled Human Malaria Infections including malaria-naïve and semi-immune individuals  
609 observed clinical cases in malaria-naïve individuals with parasites expressing VSAs; while  
610 chronic infections appeared in semi-immune with intermediate antibody levels<sup>47</sup>.  
611 Reports from the transmission season show that increasing malaria severity associates with  
612 different parasite transcriptional profiles<sup>26,48-50</sup>, but the persisting dry season reservoir had not  
613 been investigated. Our data shows that, while *P. falciparum* causing malaria in the transmission  
614 season has a ring-stage transcriptional signature, parasites persisting at the end of the dry  
615 season resemble more developed intraerythrocytic stages, which we confirmed both visually  
616 and through differential growth kinetics in vitro (Fig. 5). From the bulk RNA-Seq analysis, it is  
617 unclear if the differences in parasite gene-expression between the dry season and malaria  
618 cases are solely imposed by the hpi of the parasites collected, but single-cell transcript analysis  
619 of iRBCs<sup>5</sup> will allow comparing stage-matched pools of parasites to better understand how *P.*  
620 *falciparum* achieves low cytoadhesion in the dry season. Also of interest, will be to revisit earlier  
621 reports of transcriptional differences between parasites inducing varying degrees of malaria  
622 severity<sup>26,48,49</sup>, and question if these could be partially imposed by the number of hpi of  
623 circulating parasites. In fact, Tonkin-Hill and colleagues found a bias towards early trophozoite  
624 transcription in the non-severe malaria samples compared to the ring-stage transcriptional

625 profile of the severe malaria cases<sup>48</sup>, which could be due to differing adhesion efficiencies in  
626 vivo. Interestingly, in vitro replication rates of severe and uncomplicated malaria causing  
627 parasites<sup>51,52</sup> has not consistently explained the higher parasitaemias observed in severe  
628 malaria cases, suggesting that adhesion efficiency differences may also contribute. Continued  
629 asexual replication (independently or coupled with immunity) may lead to progressively less  
630 adhesive iRBCs as observed in parasites collected during the dry season. In a rodent-malaria  
631 model, uninterrupted asexual-stage growth led to bias in gene expression of VSA and parasite  
632 virulence<sup>53</sup>; and the transition between acute and chronic phases is suggested to be  
633 independent of adaptive immunity<sup>54</sup>. Also, in humans it has been suggested that continued  
634 asexual replication can skew the PfEMP1 expression profile<sup>47,55</sup>, which is consistent with our *var*  
635 genes RNA-Seq data (Fig. 6f and Table 2).

636 The mechanisms by which the parasite adapts to the dry season, and how transmission is  
637 assured in the rainy season ensues remain to be investigated. In a varying or unpredictable  
638 environment, organisms can overcome unfavourable conditions by sensing environmental  
639 changes and adapting their individual developmental program to increase survival; or  
640 alternatively, stochastic population heterogeneity increases the probability of survival under  
641 changing conditions<sup>56</sup>. *P. falciparum* may sense and respond to environmental cues of  
642 transmissibility opportunity, as has been described for detection of nutrient availability<sup>57</sup>, sexual  
643 commitment<sup>58</sup>, or appropriate environment for gametogenesis<sup>59</sup>. Such a mechanism could act  
644 through epigenetic modulation of VSAs, or be seasonally imposed by different metabolic states  
645 of the host, driving a shift on the parasite from a fast- to a slow-growing program as the  
646 transmission season ends and persistence is required, and return to fast growth as transmission  
647 resumes. In an avian-malaria model, chronic *P. relictum* has been shown to respond to bites  
648 from uninfected mosquitoes and increase its replication promoting transmission<sup>60</sup>. Parasite  
649 survival during the dry season is imperial, but will only be efficient in resuming transmission if  
650 these retain the ability to produce gametocytes that mosquitoes can be uptake, thus  
651 investigating potential adaptive changes in the sexual stages of *P. falciparum* during the dry  
652 season will likely also reveal seasonal adjustments.

653 The survival of *P. falciparum*-infected individuals during the dry season is advantageous for the  
654 parasite, and low adhesion of infected erythrocytes is likely a central feature to the subclinical  
655 carriage of *P. falciparum* demonstrating the adaptability of *P. falciparum* parasites to the vector-  
656 free period.

657

658 **Data availability**

659 RNA-Seq data (normalized counts data and raw sequencing reads) have been deposited in  
660 NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number  
661 GSE148125 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE148125>)  
662 All processed metabolomics spectral data and analytical metadata from this study have been  
663 deposited into the NIH Metabolomics Workbench (project ID no. #####). The data file of  
664 assembled *var* gene fragments of all isolates are available at:  
665 [https://github.com/ThomasDOtto/varDB/tree/master/Otherdatasets/Andrade\\_DryWet2020](https://github.com/ThomasDOtto/varDB/tree/master/Otherdatasets/Andrade_DryWet2020)  
666

### 667 **Acknowledgments**

668 We thank the residents of Kalifabougou, Mali for participating in this study. We acknowledge the  
669 support of the Flow Cytometry Core Facility of DKFZ in Heidelberg, Germany and the  
670 Immunology Core Lab of the UCRC in Bamako, Mali. We thank the Metabolomics Core Facility  
671 at Penn State University, and A. Patterson and P. Smith from the Penn State Metabolomics  
672 Core. This work was supported by the German Center for Infection research (DZIF), the ERC  
673 under the European Union's Horizon 2020 research and innovation programme (grant  
674 agreement No 759534), the SFB 1129 of the German Research Foundation (DFG) and the  
675 Division of Intramural Research, National Institute of Allergy and Infectious Diseases, of NIH.  
676 RTL was funded by the European Union's Horizon 2020 research and innovation programme  
677 under the Marie Skłodowska-Curie Grant Agreement No. DLV-839998.  
678

### 679 **Author contributions**

680 CMA, HF, RTL, NFL, CA, JH, CSH, SL, MN, HC, DS, CM, SR, KM, MVH, ELA and SP  
681 performed experiments and analysed data; SD, DD, KK, AO, BB and PDC designed, conducted  
682 and supervised field work generating the clinical data and samples; JM, NOS and TDO  
683 performed bioinformatic analysis; MEN, CL, TL, AM, and AF, ML provided technical expertise  
684 and TL and LT provided essential reagents; MR performed mathematical models; TMT, JS and  
685 VW provided statistics expertise; CMA prepared figures and CMA, HF, RTL, TMT, NSO and  
686 TDO and helped prepare the manuscript; TMT, AF, ML, TL, TDO, MR and PDC provided  
687 insightful comments to the manuscript. PDC discussed initial field and study designs. SP  
688 designed the study and wrote the manuscript. All authors read and approved the final  
689 manuscript.

690

691

### 692 **References**

693 1 WHO. World malaria report 2019. Report No. 978 92 4 156565 3, volumes (World Health  
694 Organization, Geneva, Switzerland, 2019).

695 2 Hommel, M., David, P. H. & Oligino, L. D. Surface alterations of erythrocytes in Plasmodium  
696 falciparum malaria. Antigenic variation, antigenic diversity, and the role of the spleen. *J Exp Med*  
697 **157**, 1137-1148, doi:10.1084/jem.157.4.1137 (1983).

698 3 Roberts, D. J. *et al.* Rapid switching to multiple antigenic and adhesive phenotypes in malaria.  
699 *Nature* **357**, 689-692, doi:10.1038/357689a0 (1992).

700 4 Bozdech, Z. *et al.* The transcriptome of the intraerythrocytic developmental cycle of Plasmodium  
701 falciparum. *PLoS Biol* **1**, E5, doi:10.1371/journal.pbio.0000005 (2003).

702 5 Howick, V. M. *et al.* The Malaria Cell Atlas: Single parasite transcriptomes across the complete  
703 Plasmodium life cycle. *Science* **365**, doi:10.1126/science.aaw2619 (2019).

704 6 Marti, M., Good, R. T., Rug, M., Knuepfer, E. & Cowman, A. F. Targeting malaria virulence and  
705 remodeling proteins to the host erythrocyte. *Science* **306**, 1930-1933,  
706 doi:10.1126/science.1102452 (2004).

707 7 Crabb, B. S. *et al.* Targeted gene disruption shows that knobs enable malaria-infected red cells to  
708 cytoadhere under physiological shear stress. *Cell* **89**, 287-296, doi:10.1016/s0092-  
709 8674(00)80207-x (1997).

710 8 Oh, S. S. *et al.* Plasmodium falciparum erythrocyte membrane protein 1 is anchored to the actin-  
711 spectrin junction and knob-associated histidine-rich protein in the erythrocyte skeleton. *Mol*  
712 *Biochem Parasitol* **108**, 237-247, doi:10.1016/s0166-6851(00)00227-9 (2000).

713 9 Lavstsen, T. *et al.* Plasmodium falciparum erythrocyte membrane protein 1 domain cassettes 8  
714 and 13 are associated with severe malaria in children. *Proc Natl Acad Sci U S A* **109**, E1791-  
715 1800, doi:10.1073/pnas.1120455109 (2012).

716 10 Lehmann, T. *et al.* Aestivation of the African malaria mosquito, Anopheles gambiae in the Sahel.  
717 *Am J Trop Med Hyg* **83**, 601-606, doi:10.4269/ajtmh.2010.09-0779 (2010).

718 11 Babiker, H. A., Abdel-Muhsin, A. M., Ranford-Cartwright, L. C., Satti, G. & Walliker, D.  
719 Characteristics of Plasmodium falciparum parasites that survive the lengthy dry season in eastern  
720 Sudan where malaria transmission is markedly seasonal. *Am J Trop Med Hyg* **59**, 582-590  
721 (1998).

722 12 Ouedraogo, A. L. *et al.* Dynamics of the Human Infectious Reservoir for Malaria Determined by  
723 Mosquito Feeding Assays and Ultrasensitive Malaria Diagnosis in Burkina Faso. *J Infect Dis* **213**,  
724 90-99, doi:10.1093/infdis/jiv370 (2016).

725 13 Portugal, S. *et al.* Treatment of Chronic Asymptomatic Plasmodium falciparum Infection Does Not  
726 Increase the Risk of Clinical Malaria Upon Reinfection. *Clin Infect Dis* **64**, 645-653,  
727 doi:10.1093/cid/ciw849 (2017).

728 14 Kimenyi, K. M., Wamae, K. & Ochola-Oyier, L. I. Understanding P. falciparum Asymptomatic  
729 Infections: A Proposition for a Transcriptomic Approach. *Front Immunol* **10**, 2398,  
730 doi:10.3389/fimmu.2019.02398 (2019).

731 15 O'Donnell, A. *et al.* The acute phase response in children with mild and severe malaria in Papua  
732 New Guinea. *Trans R Soc Trop Med Hyg* **103**, 679-686, doi:10.1016/j.trstmh.2009.03.023 (2009).

733 16 Park, G. S., Ireland, K. F., Opoka, R. O. & John, C. C. Evidence of Endothelial Activation in  
734 Asymptomatic Plasmodium falciparum Parasitemia and Effect of Blood Group on Levels of von  
735 Willebrand Factor in Malaria. *J Pediatric Infect Dis Soc* **1**, 16-25, doi:10.1093/jpids/pis010 (2012).

736 17 Bulte, F. *et al.* Circulatory hepcidin is associated with the anti-inflammatory response but not with  
737 iron or anemic status in childhood malaria. *Blood* **121**, 3016-3022, doi:10.1182/blood-2012-10-  
738 461418 (2013).

739 18 Weinberg, J. B. *et al.* Monocyte polarization in children with falciparum malaria: relationship to  
740 nitric oxide insufficiency and disease severity. *Sci Rep* **6**, 29151, doi:10.1038/srep29151 (2016).

741 19 Oyegue-Liabagui, S. L. *et al.* Pro- and anti-inflammatory cytokines in children with malaria in  
742 Franceville, Gabon. *Am J Clin Exp Immunol* **6**, 9-20 (2017).

743 20 Lyke, K. E. *et al.* Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6,  
744 IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe  
745 Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. *Infect*  
746 *Immun* **72**, 5630-5637, doi:10.1128/IAI.72.10.5630-5637.2004 (2004).

747 21 Hopp, C. S. *et al.* Plasmodium falciparum-specific IgM B cells dominate in children, expand with  
748 malaria and produce parasite inhibitory IgM. *bioRxiv*, 2020.2004.2012.030049,  
749 doi:10.1101/2020.04.12.030049 (2020).

750 22 Lavstsen, T., Salanti, A., Jensen, A. T., Arnot, D. E. & Theander, T. G. Sub-grouping of  
751 Plasmodium falciparum 3D7 var genes based on sequence analysis of coding and non-coding  
752 regions. *Malar J* **2**, 27 (2003).

753 23 Cowman, A. F., Berry, D. & Baum, J. The cellular and molecular basis for malaria parasite  
754 invasion of the human red blood cell. *J Cell Biol* **198**, 961-971, doi:10.1083/jcb.201206112  
755 (2012).

756 24 Snounou, G. *et al.* Biased distribution of msp1 and msp2 allelic variants in Plasmodium  
757 falciparum populations in Thailand. *Trans R Soc Trop Med Hyg* **93**, 369-374, doi:10.1016/s0035-  
758 9203(99)90120-7 (1999).

759 25 Liljander, A. *et al.* Optimization and validation of multi-coloured capillary electrophoresis for  
760 genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2). *Malar J* **8**, 78,  
761 doi:10.1186/1475-2875-8-78 (2009).

762 26 Daily, J. P. *et al.* Distinct physiological states of Plasmodium falciparum in malaria-infected  
763 patients. *Nature* **450**, 1091-1095, doi:10.1038/nature06311 (2007).

764 27 Rono, M. K. *et al.* Adaptation of Plasmodium falciparum to its transmission environment. *Nat Ecol*  
765 *Evol* **2**, 377-387, doi:10.1038/s41559-017-0419-9 (2018).

766 28 Lemieux, J. E. *et al.* Statistical estimation of cell-cycle progression and lineage commitment in  
767 Plasmodium falciparum reveals a homogeneous pattern of transcription in ex vivo culture. *Proc*  
768 *Natl Acad Sci U S A* **106**, 7559-7564, doi:10.1073/pnas.0811829106 (2009).

769 29 Deplaine, G. *et al.* The sensing of poorly deformable red blood cells by the human spleen can be  
770 mimicked in vitro. *Blood* **117**, e88-95, doi:10.1182/blood-2010-10-312801 (2011).

771 30 Dahlback, M. *et al.* Changes in var gene mRNA levels during erythrocytic development in two  
772 phenotypically distinct Plasmodium falciparum parasites. *Malar J* **6**, 78, doi:10.1186/1475-2875-6-  
773 78 (2007).

774 31 Otto, T. D. *et al.* Evolutionary analysis of the most polymorphic gene family in falciparum malaria.  
775 *Wellcome Open Res* **4** (2019).

776 32 Otto, T. D. *et al.* Genome sequencing of chimpanzee malaria parasites reveals possible pathways  
777 of adaptation to human hosts. *Nat Commun* **5**, 4754, doi:10.1038/ncomms5754 (2014).

778 33 Sonden, K. *et al.* Asymptomatic Multiclonal Plasmodium falciparum Infections Carried Through  
779 the Dry Season Predict Protection Against Subsequent Clinical Malaria. *J Infect Dis* **212**, 608-  
780 616, doi:10.1093/infdis/jiv088 (2015).

781 34 Males, S., Gaye, O. & Garcia, A. Long-term asymptomatic carriage of Plasmodium falciparum  
782 protects from malaria attacks: a prospective study among Senegalese children. *Clin Infect Dis* **46**,  
783 516-522, doi:10.1086/526529 (2008).

784 35 Crompton, P. D. *et al.* Sick Cell Trait Is Associated with a Delayed Onset of Malaria:  
785 Implications for Time-to-Event Analysis in Clinical Studies of Malaria. *J Infect Dis* **198**, 1265-1275,  
786 doi:10.1086/592224 (2008).

787 36 Drakeley, C., Sutherland, C., Bousema, J. T., Sauerwein, R. W. & Targett, G. A. The  
788 epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion. *Trends*  
789 *Parasitol* **22**, 424-430, doi:S1471-4922(06)00176-0 [pii]  
790 10.1016/j.pt.2006.07.001 (2006).

791 37 Bousema, T. *et al.* Mosquito feeding assays to determine the infectiousness of naturally infected  
792 Plasmodium falciparum gametocyte carriers. *PLoS One* **7**, e42821,  
793 doi:10.1371/journal.pone.0042821 (2012).

794 38 Dicko, A. *et al.* Season, fever prevalence and pyrogenic threshold for malaria disease definition in  
795 an endemic area of Mali. *Trop Med Int Health* **10**, 550-556, doi:TMI1418 [pii]  
796 10.1111/j.1365-3156.2005.01418.x (2005).

797 39 Smith, T., Schellenberg, J. A. & Hayes, R. Attributable fraction estimates and case definitions for  
798 malaria in endemic areas. *Stat Med* **13**, 2345-2358, doi:10.1002/sim.4780132206 (1994).

799 40 Staniscic, D. I., McCarthy, J. S. & Good, M. F. Controlled Human Malaria Infection: Applications,  
800 Advances, and Challenges. *Infect Immun* **86**, doi:10.1128/IAI.00479-17 (2018).

801 41 Pradeu, T. & Vivier, E. The discontinuity theory of immunity. *Sci Immunol* **1**,  
802 doi:10.1126/sciimmunol.aag0479 (2016).

803 42 Goncalves, B. P. *et al.* Examining the human infectious reservoir for *Plasmodium falciparum*  
804 malaria in areas of differing transmission intensity. *Nat Commun* **8**, 1133, doi:10.1038/s41467-  
805 017-01270-4 (2017).

806 43 Tran, T. M. *et al.* An intensive longitudinal cohort study of Malian children and adults reveals no  
807 evidence of acquired immunity to *Plasmodium falciparum* infection. *Clin Infect Dis* **57**, 40-47,  
808 doi:10.1093/cid/cit174 (2013).

809 44 Crompton, P. D. *et al.* A prospective analysis of the Ab response to *Plasmodium falciparum*  
810 before and after a malaria season by protein microarray. *Proc Natl Acad Sci U S A* **107**, 6958-  
811 6963, doi:1001323107 [pii]  
812 10.1073/pnas.1001323107 (2010).

813 45 Cham, G. K. *et al.* Hierarchical, domain type-specific acquisition of antibodies to *Plasmodium*  
814 *falciparum* erythrocyte membrane protein 1 in Tanzanian children. *Infect Immun* **78**, 4653-4659,  
815 doi:10.1093/iai.00593-10 [pii]  
816 10.1128/IAI.00593-10.

817 46 Obeng-Adjei, N. *et al.* Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant  
818 antibodies identifies associations with malaria protection. *JCI Insight*,  
819 doi:10.1172/jci.insight.137262 (2020).

820 47 Bachmann, A. *et al.* Controlled human malaria infection with *Plasmodium falciparum*  
821 demonstrates impact of naturally acquired immunity on virulence gene expression. *PLoS Pathog*  
822 **15**, e1007906, doi:10.1371/journal.ppat.1007906 (2019).

823 48 Tonkin-Hill, G. Q. *et al.* The *Plasmodium falciparum* transcriptome in severe malaria reveals  
824 altered expression of genes involved in important processes including surface antigen-encoding  
825 *var* genes. *PLoS Biol* **16**, e2004328, doi:10.1371/journal.pbio.2004328 (2018).

826 49 Almelli, T. *et al.* Differences in gene transcriptomic pattern of *Plasmodium falciparum* in children  
827 with cerebral malaria and asymptomatic carriers. *PLoS One* **9**, e114401,  
828 doi:10.1371/journal.pone.0114401 (2014).

829 50 Lee, H. J. *et al.* Integrated pathogen load and dual transcriptome analysis of systemic host-  
830 pathogen interactions in severe malaria. *Sci Transl Med* **10**, doi:10.1126/scitranslmed.aar3619  
831 (2018).

832 51 Deans, A. M. *et al.* Low multiplication rates of African *Plasmodium falciparum* isolates and lack of  
833 association of multiplication rate and red blood cell selectivity with malaria virulence. *Am J Trop*  
834 *Med Hyg* **74**, 554-563 (2006).

835 52 Chotivanich, K. *et al.* Parasite multiplication potential and the severity of *Falciparum* malaria. *J*  
836 *Infect Dis* **181**, 1206-1209, doi:10.1086/315353 (2000).

837 53 Spence, P. J. *et al.* Vector transmission regulates immune control of *Plasmodium* virulence.  
838 *Nature* **498**, 228-231, doi:10.1038/nature12231 (2013).

839 54 Brugat, T. *et al.* Antibody-independent mechanisms regulate the establishment of chronic  
840 *Plasmodium* infection. *Nat Microbiol* **2**, 16276, doi:10.1038/nmicrobiol.2016.276 (2017).

841 55 Abdi, A. I. *et al.* Global selection of *Plasmodium falciparum* virulence antigen expression by host  
842 antibodies. *Sci Rep* **6**, 19882, doi:10.1038/srep19882 (2016).

843 56 Weinberger, L. S. A minimal fate-selection switch. *Curr Opin Cell Biol* **37**, 111-118,  
844 doi:10.1016/j.ceb.2015.10.005 (2015).

845 57 Mancio-Silva, L. *et al.* Nutrient sensing modulates malaria parasite virulence. *Nature* **547**, 213-  
846 216, doi:10.1038/nature23009 (2017).

847 58 Brancucci, N. M. B. *et al.* Lysophosphatidylcholine Regulates Sexual Stage Differentiation in the  
848 Human Malaria Parasite *Plasmodium falciparum*. *Cell* **171**, 1532-1544 e1515,  
849 doi:10.1016/j.cell.2017.10.020 (2017).

850 59 Billker, O. *et al.* Identification of xanthurenic acid as the putative inducer of malaria development  
851 in the mosquito. *Nature* **392**, 289-292, doi:10.1038/32667 (1998).

852 60 Cornet, S., Nicot, A., Rivero, A. & Gandon, S. Evolution of plastic transmission strategies in avian  
853 malaria. *PLoS pathogens* **10**, e1004308, doi:10.1371/journal.ppat.1004308 (2014).

854

855